Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tofacitinib-induced paradoxical psoriasis in a patient with ankylosing spondylitis: A case report.

Annales de dermatologie et de venereologie·2026

Same author

A unique anatomical variation: the supradiaphragmatic origination from thoracic aorta of multiple visceral organ arteries.

Annals of the Royal College of Surgeons of England·2025

Same author

Prevalence of insulin dysregulation in the non-obese stock-type horse and relationship with morphometric neck measurements.

Journal of equine veterinary science·2024

Same author

Arerugi = [Allergy]·2023

Same author

Keokuk County Medical Society.

Iowa medical journal·2023

Same author

Conceptualization and implementation of the Fiber Utilization and Cell Wall Constituents Symposium.

Journal of animal science·2023

Search research articles

Related Experiment Video

Updated: May 9, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

PDE5 inhibitors: considerations for preference and long-term adherence.

W B Smith¹, I R McCaslin, A Gokce

¹Department of Urology, School of Medicine, Tulane University, New Orleans, LA, USA.

International Journal of Clinical Practice

|July 23, 2013

Summary

Phosphodiesterase type 5 inhibitors (PDE5i) are effective first-line treatments for erectile dysfunction (ED). Understanding drug profiles and improving patient-provider communication enhances long-term treatment success.

Related Experiment Videos

Last Updated: May 9, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Urology
Pharmacology
Men's Health

Background:

Erectile dysfunction (ED) affects nearly 20% of men globally.
Phosphodiesterase type 5 inhibitors (PDE5i) have transformed ED treatment, offering effective, minimally invasive options.

Purpose of the Study:

To review the pharmacokinetics, efficacy, and comparative profiles of available PDE5i.
To explore strategies for improving long-term treatment adherence and success.

Main Methods:

A literature search of English-language articles from 1996 to the present was conducted on PDE5i.
The search included studies on pharmacokinetics, efficacy, and comparative data.

Main Results:

Available PDE5i (sildenafil, vardenafil, tadalafil, avanafil) have distinct side effect and pharmacokinetic profiles.
Initial response rates to PDE5i are 60-70%, with no clear preference for a single agent.
High success rates (89%) were observed when patients were prescribed multiple PDE5i; daily tadalafil improved erectile function over time.

Conclusions:

PDE5i are first-line therapies for ED, demonstrating high efficacy and acceptable side effect profiles.
Improved patient-provider communication and knowledge of drug characteristics can enhance long-term treatment outcomes.